GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the investor's long-term strategy, beginner-level knowledge, and available funds, Gilead Sciences Inc (GILD) is a good buy. The company demonstrates strong financial growth, positive analyst sentiment, and promising catalysts in its HIV franchise and cell therapy pipeline. Despite short-term technical weakness, the long-term outlook remains favorable.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 36.883, and moving averages are converging. The stock is trading near its support level of 144.23, with resistance at 151.996. Short-term technical indicators suggest weakness, but no clear reversal signal is present.
Strong financial performance in Q4 2025, with revenue up 4.7% YoY and net income up 22.43% YoY.
Analysts have raised price targets, with several maintaining Buy or Outperform ratings.
Promising developments in the HIV franchise and the upcoming launch of Sanito-Cel, which could add up to $20 billion in value.
Acquisition of Arcellx strengthens Gilead's position in cell therapy.
Short-term bearish technical indicators, including a negative MACD and price trading near support levels.
Barclays views the current valuation as 'rich,' which may limit immediate upside potential.
No significant hedge fund or insider trading activity to indicate strong institutional conviction.
In Q4 2025, Gilead reported revenue of $7.925 billion, up 4.7% YoY. Net income increased by 22.43% YoY to $2.183 billion, while EPS rose 25.18% YoY to $1.74. Gross margin improved slightly to 79.51%. These results highlight strong growth, driven by the HIV franchise.
Analysts are generally positive on Gilead, with multiple firms raising price targets recently. UBS, Mizuho, and Morgan Stanley have targets ranging from $170 to $175, citing strong performance in the HIV franchise and promising developments in long-acting therapies. However, Barclays has an Equal Weight rating, citing valuation concerns.
